BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines aBRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M)
Form 10-Q / 10-K Segment Disaggregation Note (XBRL)
Latest, FY2021
0
Period ended Dec 31, 2021
Change on a year earlier
-100.0%
17.8 in FY2020
History
4 years
Since FY2018
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | -100.0% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 17.8 | -84.0% | Form 10-K (filed 2022-02-28) ↗ |
| FY2019 | Dec 31, 2019 | 111 | +56.3% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 71.2 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines ABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M), annual FY2018–FY2021 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_abraxane
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.